Core Team
Weidong Jiang, Ph.D, Founder & CEO
Co-founder, Shanghai Henlius Biotech Inc. 
B.S. from Hangzhou University (Zhejiang University) M.S. from Shanghai Institute of Cell Biology, Chinese Academy of Sciences, Ph.D. from Giessen University, Germany, Post-doc from University of California, USA.
Worked at ChemGenics (Millennium/Takeda), Microcide, Applied Molecular Evolution (Eli Lilly) and Catalyst Biosciences as Sr. scientists and directors, with rich industrial experience including drug discovery, development, and management, particularly in antibody and biological therapeutics.
Co-founded Shanghai Henlius Biotech Inc. in 2009, and Hengenix/Henlix as a discovery arm. Henlius went to public in Hongkong stock exchange in Sept., 2019. Currently Henlius has five commercial antibody products on the Chinese market as well as one antibody product in European market, and with a rich pipeline of over 20 products in global clinical trials.
Haixiang Wu, Ph.D, CMC VP
Dr. Haixiang Wu, Vice President of CMC, graduated from Wuhan University, with nearly 20 years of experience in new drug research and development, particularly on recombinant protein and antibody drugs, rich experience in IND projects in China and the United States, covering TAA and I/O targets, and cytokine drugs.
Dr. Wu has rich experience in a variety of expression systems, skilled in candidate selection, host cell genetic engineering, efficient and stable cell line construction.
More than 10 successful IND projects in pharmaceutical research, including cell culture process development, bioreactor optimization, downstream purification, and formulation development, analytical method development and validation, pilot production, batch release and product characterization, stability studies, and clinical sample production and supply.
